Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
Go back to Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)| (NASDAQ: NTRA) | Delayed: 225.80 -5.61 (2.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $231.41 | 52 Week High | $13.80 | |||
| Open | $231.52 | 52 Week Low | $6.52 | |||
| Day High | $234.14 | P/E | N/A | |||
| Day Low | $219.50 | EPS | $0.00 | |||
| Volume | 877,445 | |||||
